Use lowest effective dose for shortest possible time. Discontinue at the 1st appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Risk of upper & lower GI complications (perforations, ulcers or bleedings), especially in patients w/ risk factors for GI complication. Increased risk of CV thrombotic events, MI, & stroke, especially in long-term use & in patients w/ risk factors for CV events. Long-term administration of NSAIDs has resulted in renal papillary necrosis & other renal injury. Risk of renal toxicity, especially in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. Not recommended in patients w/ advanced renal disease. Risk of fluid retention & oedema. Can lead to onset of new HTN or worsening of pre-existing HTN; closely monitor BP during treatment initiation & throughout course of therapy. Reports of severe hepatic reactions including fulminant hepatitis, liver necrosis & hepatic failure. May mask fever & other signs of inflammation. Concomitant use w/ CYP2D6 substrates; warfarin or other oral anticoagulants, including novel anticoagulants (eg, apixaban, dabigatran, rivaroxaban). Avoid concomitant non-aspirin NSAIDs. CYP2C9 poor metabolisers; patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption; moderate liver impairment w/ serum albumin 25-35 g/L; mild or moderate renal impairment; elderly, especially those w/ body wt <50 kg. Patients who experience dizziness, vertigo or somnolence while taking celecoxib should refrain from driving or operating machinery. May delay or prevent rupture of ovarian follicles, which has been associated w/ reversible infertility in some women. Not indicated for use in childn.
Sign Out
